EQL Pharma AB (publ) (STO:EQL)

EQL Pharma AB Statistics

Total Valuation

EQL Pharma AB has a market cap or net worth of SEK 1.48 billion. The enterprise value is 1.85 billion.

Market Cap	1.48B
Enterprise Value	1.85B

Important Dates

The next estimated earnings date is Tuesday, February 3, 2026.

Earnings Date	Feb 3, 2026
Ex-Dividend Date	n/a

Share Statistics

EQL Pharma AB has 29.53 million shares outstanding. The number of shares has increased by 3.09% in one year.

Current Share Class	29.53M
Shares Outstanding	29.53M
Shares Change (YoY)	+3.09%
Shares Change (QoQ)	+3.05%
Owned by Insiders (%)	2.31%
Owned by Institutions (%)	11.12%
Float	21.74M

Valuation Ratios

The trailing PE ratio is 51.27 and the forward PE ratio is 30.77.

PE Ratio	51.27
Forward PE	30.77
PS Ratio	3.70
PB Ratio	5.68
P/TBV Ratio	n/a
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Enterprise Valuation

The stock's EV/EBITDA ratio is 25.29, with an EV/FCF ratio of -96.24.

EV / Earnings	62.36
EV / Sales	4.63
EV / EBITDA	25.29
EV / EBIT	29.85
EV / FCF	-96.24

Financial Position

The company has a current ratio of 2.03, with a Debt / Equity ratio of 1.72.

Current Ratio	2.03
Quick Ratio	0.98
Debt / Equity	1.72
Debt / EBITDA	6.14
Debt / FCF	-23.37
Interest Coverage	2.59

Financial Efficiency

Return on equity (ROE) is 12.93% and return on invested capital (ROIC) is 7.33%.

Return on Equity (ROE)	12.93%
Return on Assets (ROA)	6.19%
Return on Invested Capital (ROIC)	7.33%
Return on Capital Employed (ROCE)	9.81%
Revenue Per Employee	18.14M
Profits Per Employee	1.35M
Employee Count	21
Asset Turnover	0.64
Inventory Turnover	1.36

Taxes

In the past 12 months, EQL Pharma AB has paid 7.73 million in taxes.

Income Tax	7.73M
Effective Tax Rate	20.70%

Stock Price Statistics

The stock price has decreased by -31.20% in the last 52 weeks. The beta is 0.54, so EQL Pharma AB's price volatility has been lower than the market average.

Beta (5Y)	0.54
52-Week Price Change	-31.20%
50-Day Moving Average	57.37
200-Day Moving Average	76.42
Relative Strength Index (RSI)	34.18
Average Volume (20 Days)	30,945

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, EQL Pharma AB had revenue of SEK 399.07 million and earned 29.61 million in profits. Earnings per share was 0.98.

Revenue	399.07M
Gross Profit	162.81M
Operating Income	61.86M
Pretax Income	37.34M
Net Income	29.61M
EBITDA	71.23M
EBIT	61.86M
Earnings Per Share (EPS)	0.98

Balance Sheet

The company has 78.26 million in cash and 448.37 million in debt, giving a net cash position of -370.10 million or -12.53 per share.

Cash & Cash Equivalents	78.26M
Total Debt	448.37M
Net Cash	-370.10M
Net Cash Per Share	-12.53
Equity (Book Value)	260.00M
Book Value Per Share	8.80
Working Capital	200.02M

Cash Flow

In the last 12 months, operating cash flow was -8.18 million and capital expenditures -11.01 million, giving a free cash flow of -19.19 million.

Operating Cash Flow	-8.18M
Capital Expenditures	-11.01M
Free Cash Flow	-19.19M
FCF Per Share	-0.65

Margins

Gross margin is 40.80%, with operating and profit margins of 15.50% and 7.42%.

Gross Margin	40.80%
Operating Margin	15.50%
Pretax Margin	9.36%
Profit Margin	7.42%
EBITDA Margin	17.85%
EBIT Margin	15.50%
FCF Margin	n/a

Dividends & Yields

EQL Pharma AB does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-3.09%
Shareholder Yield	-3.09%
Earnings Yield	2.01%
FCF Yield	-1.30%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value
Lynch Upside
Graham Number
Graham Upside

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Altman Z-Score	n/a
Piotroski F-Score	3